Latest news
Akeso Doses First Patient in Phase II Trial of Dual-Targeting ADC Plus Ivonescimab for Advanced Breast Cancer - finance.biggo.comfinance.biggo.com · Mon, 10 Aug 2026 18:43:00 GMTAkeso Doses First Patient in Phase 2 Trial of Bispecific ADC AK146D1 Plus Ivonescimab in Breast Cancer - BioPharm InternationalBioPharm International · Mon, 10 Aug 2026 16:47:15 GMT